Adding a GLP-1 to Diabetes Medication: What Comes Down First

4 min read · doses off DailyMed · last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

A GLP-1 lowers blood sugar largely by amplifying the insulin response you already produce and damping the hormone that raises glucose. Both effects are glucose-dependent: when your sugar is not high, they largely stand down. That is why these drugs cause remarkably little hypoglycemia by themselves.

Insulin and sulfonylureas have no such brake. They push insulin out whether or not it is wanted. Layer a GLP-1 on top without touching them and the combination becomes the danger. Every one of these labels warns about it, and it is why something usually has to come down before the GLP-1 goes up.

What to do with each

What to do with each
MedicationExamplesTypically
Long-acting insulinLantus, Tresiba, Toujeo, Levemir, BasaglarComes down, commonly by about a fifth to a quarter at the start, and further if your numbers are already at target.
Mealtime insulinHumalog, NovoLog, Apidra, Lyumjev, FiaspComes down more, often by a quarter to a half, because you are about to eat less. Some people stop it altogether once the GLP-1 reaches a working dose, and one trial replaced basal-bolus insulin with a single weekly combination injection.
SulfonylureasGlipizide, glimepiride, glyburideOften stopped, or roughly halved if kept. This is the highest-hypoglycemia oral class, and adding a GLP-1 is a natural moment to reconsider it.
MeglitinidesRepaglinide, nateglinideSame logic as sulfonylureas — halved or stopped.
MetforminGlucophage, Glumetza, FortametUnchanged. Almost no hypoglycemia risk of its own and a natural partner to a GLP-1.
SGLT2 inhibitorsJardiance, Farxiga, InvokanaUnchanged. Different mechanism, no shared hypoglycemia risk, and heart and kidney benefits of their own.
DPP-4 inhibitorsJanuvia, Tradjenta, OnglyzaStopped. They work on the same incretin pathway a GLP-1 now occupies far more powerfully, so they add nothing.
PioglitazoneActosUnchanged, though fluid retention can disguise weight progress.
Another GLP-1Victoza, Saxenda, Trulicity, ByettaOne stops before the other starts. The Wegovy, Zepbound and Saxenda labels say combining one with any other GLP-1 is not recommended.

On those percentages. The labels themselves say to consider reducing the insulin or secretagogue dose without naming a figure. The numbers above come from common clinical practice, and your prescriber will adjust to your own readings. Do not change insulin on the strength of a reference card.

Recognizing a hypo

The early signs are physical and easy to dismiss as something else.

  • Shaking or trembling hands, usually the first sign.
  • Cold sweat or clammy skin with no reason to be sweating.
  • Confusion, trouble concentrating, slurred words.
  • Dizziness or feeling about to faint.
  • A pounding or racing heart.
  • Blurred vision, sudden irritability, sudden hunger, headache.

Treat it with roughly 15 to 20 grams of fast sugar: a small glass of juice, a few glucose tablets, a spoon of honey or a handful of hard candy. Wait a quarter of an hour, test again, and repeat if you are still below 70 mg/dL.

Checking it is working

Standard practice is an A1C every three months until you are at target, then twice a year. After a GLP-1 goes in, most prescribers look sooner, with a fasting glucose or a continuous-monitor snapshot at four to eight weeks, to catch over-correction before the formal three-month reading.

That first proper A1C tells you whether the reduction you made at the start was right, insufficient, or too much.

Call your prescriber if

  • A severe hypo. Passing out, a seizure, or needing someone else to help you. A single one warrants a same-day call.
  • Three or more mild lows inside a week, even ones you handled yourself. The other drug is too high.
  • A1C drifting under 6.0% while still on insulin or a sulfonylurea. It looks like success but carries real risk.
  • Fasting glucose under 80 mg/dL for a week or more. The basal insulin needs to come down again.
  • Readings below 60 mg/dL that you cannot feel at all. Losing hypo awareness means the regimen needs rethinking now.

What this does not cover

Diabetes co-medication only. It does not cover the non-diabetes interactions, such as how a slowed stomach affects the contraceptive pill, levothyroxine timing or warfarin monitoring. Nor type 1 diabetes, diabetes in pregnancy, children, or ketoacidosis planning. Sick days and surgery have their own page.

Nothing here is a reason to change an insulin dose on your own. Use it to prepare for that conversation with your prescriber.

Where to go next

References

  1. 1.U.S. National Library of Medicine — DailyMed. OZEMPIC (semaglutide) — Structured Product Label (section 5.5 hypoglycemia + section 7 drug interactions). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  2. 2.U.S. National Library of Medicine — DailyMed. MOUNJARO (tirzepatide) — Structured Product Label (section 5.3 hypoglycemia + section 7 drug interactions). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  3. 3.American Diabetes Association. Standards of Care in Diabetes — 2025: Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2025. https://diabetesjournals.org/care/issue/48/Supplement_1
  4. 4.U.S. National Library of Medicine — DailyMed. WEGOVY (semaglutide) — Structured Product Label (section 1, limitations of use: coadministration with another GLP-1 receptor agonist). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  5. 5.U.S. National Library of Medicine — DailyMed. ZEPBOUND (tirzepatide) — Structured Product Label (section 1, limitations of use: coadministration with another GLP-1 receptor agonist). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  6. 6.U.S. National Library of Medicine — DailyMed. SAXENDA (liraglutide) — Structured Product Label (section 1, limitations of use: coadministration with another GLP-1 receptor agonist). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143

Frequently Asked Questions

Usually yes, and before the GLP-1 goes up rather than after. Long-acting insulin commonly comes down by around a fifth to a quarter at the start, and mealtime insulin further still, by a quarter to a half, since you are about to eat noticeably less. Some people come off mealtime insulin entirely once the GLP-1 reaches a working dose. Those figures reflect common practice rather than anything the label specifies, so the adjustment belongs to whoever manages your diabetes.
Frequently, and if kept they are usually roughly halved. Sulfonylureas push insulin out regardless of your blood sugar, which makes them the oral drug most likely to cause a hypo, and adding a GLP-1 is a sensible moment to ask whether they are still earning their place. Meglitinides such as repaglinide follow the same reasoning.
Both, at full dose, with no adjustment. Neither carries meaningful hypoglycemia risk on its own, and an SGLT2 inhibitor works by an entirely separate route and brings cardiovascular and kidney benefits of its own. These are the straightforward companions.
No. A DPP-4 inhibitor comes off. It works by preserving your own incretin hormones, which is a modest version of what the GLP-1 is now doing far more powerfully. Keeping both means paying for two drugs to occupy one pathway, with no added benefit to show for it.
Roughly 15 to 20 grams of fast-acting sugar (a small glass of juice, a few glucose tablets or a spoonful of honey), then wait fifteen minutes and test again, repeating if you are still under 70 mg/dL. If you are getting three or more of these a week, or any episode where someone had to help you, the co-medication dose is wrong and that is a call to your prescriber rather than something to manage with more juice.

Editorial reference content, not medical advice. Changing a dose, holding one, or stopping altogether is a decision for you and your prescriber together. As for the numbers: we checked every dose figure here against the FDA-approved Structured Product Label on DailyMed in October 2026.

Browse all cheat sheets, top-N research lists, or long-form research deep-dives.